Kern Capital

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Apton Biosystems, Inc. is a biotechnology company based in Pleasanton, California, founded in 2012. The company specializes in developing advanced optical systems for sequencing and protein detection, utilizing super-resolution technology to analyze molecules that are spaced closer than the wavelength of light. This innovative approach facilitates multi-omic sequencing and single-molecule protein detection, significantly enhancing capabilities in biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems aims to advance preventive health and precision medicine by addressing spatial challenges in high-density sequencing and protein analysis, thus contributing to improved healthcare outcomes.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.